Current Medical Science

, Volume 39, Issue 2, pp 211–216 | Cite as

Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy

  • Na Shen
  • Yong You
  • Zhao-dong Zhong
  • Li Meng
  • Jian-feng Zhou
  • Ping Zou
  • Xiao-jian Zhu
  • Hong-xiang WangEmail author
  • Fan-jun ChengEmail author


Discontinuation of tyrosine kinase inhibitor (TKI) therapy after achieving a persistent deep molecular response (DMR) is an urgently needed treatment goal for chronic myeloid leukemia (CML) patients and has been included in the National Comprehensive Cancer Network (NCCN) guidelines (version 2.2017) for CML. Indeed, various studies have confirmed the feasibility of discontinuing TKI therapy. In this study, we analyzed data from 45 CML patients who had discontinued TKI therapy. Univariate analysis was performed to predict factors that were potentially related to treatment-free remission (TFR) and identify the differences between early relapse and late relapse. Out of the 45 patients, 20 exhibited molecular relapse after a median follow-up of 18 months (range, 1–54 months), and the estimated TFR at 24 months was 40%. The univariate analysis revealed that a high Sokal score and interruptions or dose reductions during TKI treatment were the only baseline factors associated with poor outcomes. Our results indicate that TKI discontinuation could be successfully put into practice in China.

Key words

discontinuation treatment-free remission chronic myeloid leukemia relapse 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst, 2011,103(7):553–561CrossRefGoogle Scholar
  2. 2.
    Mughal TI, Radich JP, Deininger MW, et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica, 2016,101(5):541–558CrossRefGoogle Scholar
  3. 3.
    Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol, 2014,32(5):415–423CrossRefGoogle Scholar
  4. 4.
    Castagnetti F, Gugliotta G, Breccia M, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia, 2015,29(9):1823–1831CrossRefGoogle Scholar
  5. 5.
    Mauro MJ. Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia. Leuk Res, 2013,37(11):1395–1403CrossRefGoogle Scholar
  6. 6.
    Jiang Q, Liu ZC, Zhang SX, et al. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol, 2016,142(7):1539–1547CrossRefGoogle Scholar
  7. 7.
    Jabbour E. Chronic myeloid leukemia: First-line drug of choice. Am J Hematol, 2016,91(1):59–66CrossRefGoogle Scholar
  8. 8.
    Mahon FX. Discontinuation of tyrosine kinase therapy in CML. Ann Hematol, 2015,94 Suppl 2:S187–S193CrossRefGoogle Scholar
  9. 9.
    Breccia M, Colafigli G, Molica M, et al. Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. Am J Hematol, 2017,92(12):E668–E670CrossRefGoogle Scholar
  10. 10.
    Saussele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia, 2016,30(8):1638–1647CrossRefGoogle Scholar
  11. 11.
    Rea D, Mahon FX. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy. Br J Haematol, 2018,180(1):24–32CrossRefGoogle Scholar
  12. 12.
    Brown PA, Shah B, Fathi A, et al. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw, 2017,15(9):1091–1102CrossRefGoogle Scholar
  13. 13.
    Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013,122(6):872–884CrossRefGoogle Scholar
  14. 14.
    Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 2010,11(11):1029–1035CrossRefGoogle Scholar
  15. 15.
    Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 2013,122(4):515–522CrossRefGoogle Scholar
  16. 16.
    Legros L, Nicolini FE, Etienne G, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer, 2017,123(22):4403–4410CrossRefGoogle Scholar
  17. 17.
    Etienne G, Guilhot J, Rea D, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol, 2017,35(3):298–305CrossRefGoogle Scholar
  18. 18.
    Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica, 2012,97(6):903–906CrossRefGoogle Scholar
  19. 19.
    Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood, 2011,118(13):3657–3660CrossRefGoogle Scholar
  20. 20.
    Warfvinge R, Geironson L, Sommarin M, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood, 2017,129(17):2384–2394CrossRefGoogle Scholar
  21. 21.
    Li Q, Zhong Z, Zeng C, et al. A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. Oncotarget, 2016,7(36):58234–58243Google Scholar
  22. 22.
    Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget, 2016,7(23):35293–35301CrossRefGoogle Scholar
  23. 23.
    Breccia M, Alimena G. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett, 2014,347(1):22–28CrossRefGoogle Scholar
  24. 24.
    Li F, He B, Ma X, et al. Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. Cell Stem Cell, 2017,21(3):359–373CrossRefGoogle Scholar
  25. 25.
    Ilander M, Olsson-Stromberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia, 2017,31(5):1108–1116CrossRefGoogle Scholar
  26. 26.
    Mustjoki S, Richter J, Barbany G, et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia, 2013,27(7):1520–1526CrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology 2019

Authors and Affiliations

  • Na Shen
    • 1
  • Yong You
    • 1
  • Zhao-dong Zhong
    • 1
  • Li Meng
    • 2
  • Jian-feng Zhou
    • 2
  • Ping Zou
    • 1
  • Xiao-jian Zhu
    • 2
  • Hong-xiang Wang
    • 3
    Email author
  • Fan-jun Cheng
    • 1
    Email author
  1. 1.Institute of Hematology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Hematology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  3. 3.Department of HematologyThe Central Hospital of WuhanWuhanChina

Personalised recommendations